SARS-CoV-2 Neutralizing Antibodies discovered using upfront blocking assay

29 January, 2021

At Antibody Engineering & Therapeutics 2020 virtual conference, SCT presented a poster titled "SARS-CoV-2 Neutralizing Antibodies Discovered Fast: A Novel Blocking assay to Speed to the Finish." This poster highlights our work on SARS-CoV-2, the virus that causes COVID-19. Our work is still in progress.

To view the poster, click here.

To view Allison Schulkins 5 minute presentation of the poster, check out the embedded vimeo link below.

SARS-CoV-2 Neutralizing Antibodies Discovered Fast: A Novel Upfront Blocking Assay to Speed to the Finish from Allison Schulkins on Vimeo.

Recent News

New mechanism that predicts a competitive advantage to SARS-CoV-2 virus carrying the D614G spike mutation

Jun 15, 2020

A manuscript studying a prominent mutation in SARS-CoV-2 has been published on a preprint server by partners Single Cell Technology and Antibody Solutions.

Read More+

SCT to present candidate selection workflow at Antibody Engineering & Therapeutics

Jun 15, 2020

SCT to present a candidate selection workflow of AbTheneum output at Antibody Engineering & Therapeutics using BCMA, TIGIT, and TIM3 to demonstrate the year-long effort. The presentation will be given on Wednesday, December 11 at the Marriott Marquis in San Diego…

Read More+

ACROBiosystems brings high affinity anti-BCMA antibodies, attending Fifteenth Annual PEGS Boston 2019

Apr 8, 2019

ACROBiosystems, a leading manufacturer of recombinant proteins and critical reagents to the biopharma industry, today announced at the PEGS – Protein Engineering Summit the successful completion of isolation and characterization of a large panel of anti-human BCMA antibodies for the purpose of treating multiple myeloma cancer.

Read More+